Post-market utilization patterns of Alzheimer’s disease treatments in South Korea: comparison with countries with universal health coverage
- 6 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 77 (6), 921-929
- https://doi.org/10.1007/s00228-020-03065-x
Abstract
Purpose This study aimed to compare the utilization of Alzheimer’s disease (AD) treatments, donepezil, galantamine, rivastigmine, and memantine, in Korea with Australia and other countries with universal health coverage. Methods Reimbursement criteria and the patent status of four AD treatments in Korea and Australia were reviewed. The monthly spending and utilization of the treatments were extracted from the national electronic database in Korea and Australia. The defined daily dose per 1000 elderly population per day (DDD/1000e/day) were calculated from July 2008 to June 2019. Annual cost trends of Norway and England were compared with Korea and Australia. Results With the highest share of the use of donepezil in both countries, the cost and utilization of AD treatments in Korea increased more rapidly and remained higher than Australia. The cost of AD treatments in Korea increased by 15.5% every year during the study period, while the spending of the same drugs in Australia decreased by 10.5% annually. The utilization in DDD/1000e/day of AD treatments in Korea increased by 18.3% annually compared with 1.4% in Australia. When compared with Norway and England, countries with similar universal health coverage (UHC) system and elderly polupation, the cost of AD treatments in Korea was still higher with the opposite trend from other countries. Conclusions Despite the similar UHC systems, there were considerable differences in the post-market utilization of AD treatments in Korea from Australia and other countries. This results can be attributed to differences in re-assessment system, pricing and reimbursement policies, and prescribing culture. This study provides a baseline to explore more comprehensive cross-country studies on rational use of medicines.Keywords
Funding Information
- National Health and Medical Research Council and Australian Research Council (APP1101788)
This publication has 13 references indexed in Scilit:
- Past and Future of Drug Treatments for Alzheimer's DiseaseJournal of Korean Neuropsychiatric Association, 2018
- Clinical practice guidelines for dementia in AustraliaThe Medical Journal of Australia, 2016
- Alzheimer's Disease therapeutics: current and future therapies.2016
- Trends in Prescription Drug Use Among Adults in the United States From 1999-2012JAMA, 2015
- The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010BMC Medicine, 2015
- Pharmacological Treatment of DementiaBrain & Neurorehabilitation, 2015
- Prevalence and Predictors of Polypharmacy among Korean ElderlyPLOS ONE, 2014
- Multicentre population‐based dementia prevalence survey in Japan: a preliminary reportPsychogeriatrics, 2012
- Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice GuidelineAnnals of Internal Medicine, 2008
- Changing Relative Prevalence of Alzheimer Disease versus Non-Alzheimer Disease Dementias: Have We Underestimated the Looming Dementia Epidemic?Dementia and Geriatric Cognitive Disorders, 2006